CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. DOUBLE ASTERISKS DENOTE SUCH OMISSIONS.Master Formulation Development Agreement • August 1st, 2017 • Edge Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Amended and Restated Master Formulation Development Agreement (the “Agreement”), dated June 30, 2017 (the “Amendment and Restatement Effective Date”), is made by and between Oakwood Laboratories, L.L.C., a Delaware limited liability company having an address of 7670 First Place, Suite A, Oakwood Village, OH 44146 (“Oakwood”), and Edge Therapeutics, Inc., a New Jersey corporation having an address of 300 Connell Drive, Suite 4000, Berkeley Heights, NJ 07922 (“Edge”). Edge and Oakwood are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
MANUFACTURING AND SUPPLY AGREEMENT BETWEEN EDGE THERAPEUTICS, INC. AND OAKWOOD LABORATORIES, L.L.C. June 30, 2017Manufacturing Agreement • August 1st, 2017 • Edge Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This MANUFACTURING AND SUPPLY AGREEMENT (this “Agreement”), dated as of June 30, 2017 (the “Effective Date”), is made by and between Edge Therapeutics, Inc., having a place of business at 300 Connell Drive, Suite 4000, Berkeley Heights, NJ 07922 (“Edge”) and Oakwood Laboratories, L.L.C., a limited liability company organized and existing under the laws of Delaware having an address of 7670 First Place, Suite A, Oakwood Village, OH 44146 (“Oakwood”). Edge and Oakwood are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
